Incyte signs $77.5M collaboration and licensing deal with Chinese biopharmaceutical company
July 02, 2019 at 10:56 AM EDT
The deal, which involves an Incyte monoclonal antibody being developed as a cancer treatment, includes a $17.5 million upfront payment.
